Back to results
Bibliographic record · Consultation and access
Revista científica

RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts

Rodríguez, Maria Sol et al · Fundación Revista Medicina · 2021

Open-access full text
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.

Resource access

Elegí el proveedor desde el que querés acceder.

CONICET Digital CONICET Digital OAI-PMH
Entrar por CONICET Digital
Main access

Open-access full text

Texto completo identificado como acceso abierto.
Open text
Otras opciones de acceso Elegí el proveedor disponible para esta ficha.
CONICET Digital OAI-PMH
Acceder por CONICET Digital OAI-PMH
eLibro Cátedra · Actualización completa julio 2026 eLibro Cátedra
Acceder por eLibro Cátedra · Actualización completa julio 2026

Other available options

When the resource is available on more than one platform, you can choose where to open it.

CONICET Digital OAI-PMH Access available
Open
eLibro Cátedra · Actualización completa julio 2026 eLibro Cátedra Access available
Open

Summary

Descripción general del contenido del recurso.

T47D and IBH6 cells that overexpress RUNX2 show high levels of FGFR2 and FGF2, supporting the hypothesis that FGF2 increases RUNX2 and, in turn, RUNX2 increases FGF2, maintaining a positive loop. However, in these models RUNX2 overexpression generates tumors resistant to FGFR inhibitor therapy and show a more aggressive phenotype compared with control tumors.T47D and IBH6 are luminal breast cancer cells that express ER and PR. Our goal is to explore the role of RUNX2 and its relationship with hormone receptors in BrCa. The aim of this work was to evaluate the effect of endocrine therapy in RUNX2 overexpressing tumors.RUNX2 and control cells (C, empty vector) were injected into the flank of NSG mice. Animals were treated for 3 weeks with an antiestrogen (Fulvestrant FUL, 0.5mg/week) or an antiprogestin (MFP, 6mg pellets). Control tumors showed a significant growth inhibition with the therapy (C-T47D p<0.0001 C vs FUL and MFP; C-IBH6 p<0.0001 C vs FUL), a lower Ki67 index (C-T47D: p<0.0001 C vs FUL, p<0.05 C vs MFP, C-IBH6 p<0.05 C vs FUL) and higher stromal remodeling compared with untreated ones. In both models, RUNX2 tumors were resistant to endocrine therapy and all animals bearing RUNX2-T47D tumors developed lung metastasis. Our conclusion is that RUNX2 promotes BrCa progression and is a key player in the acquisition of endocrine resistance. We emphasize the development of RUNX2 inhibitors to use in combination with standard therapy for BrCa treatment. Fil: Rodríguez, Maria Sol. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Riggio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Rodríguez, M. S. E. A. (2021). RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts. http://hdl.handle.net/11336/152261

MLA

Rodríguez, Maria Sol et al. "RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts." 2021. http://hdl.handle.net/11336/152261.

Chicago

Rodríguez, Maria Sol et al. 2021. "RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts.". http://hdl.handle.net/11336/152261.

Harvard

Rodríguez, M. S. E. A. 2021, RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts, Fundación Revista Medicina, available at: http://hdl.handle.net/11336/152261 [Accessed 8 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts
Author / contributors
Rodríguez, Maria Sol et al
Publisher
Fundación Revista Medicina
Publication year
2021
ISSN
0025-7680
ISSN
0025-7680
Language
English

Subjects

Explore related resources through these subjects.

Copied